# Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

Study · id `cardio:ct-nct02021318` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02021318](<https://clinicaltrials.gov/study/NCT02021318>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02021318

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 616 participants.

## Technical summary

Registry record NCT02021318. Randomized; no masking; primary purpose treatment. Start 2014-03-12 (actual); primary completion 2018-03-23 (actual). Results posted on 2021-03-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 616 participants (enrolled count; ClinicalTrials.gov record NCT02021318, source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)
- Started: 2014-03-12 (actual) (ClinicalTrials.gov record NCT02021318, source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)
- Primary completion: 2018-03-23 (actual) (ClinicalTrials.gov record NCT02021318, source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)
- Completion: 2019-11-06 (actual) (ClinicalTrials.gov record NCT02021318, source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)
- Results first posted: 2021-03-29 (ClinicalTrials.gov record NCT02021318, source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)
- Countries: Austria; Belarus; Bulgaria; Croatia; Czechia; Finland; France; Georgia; Germany; Hungary; Ireland; Israel; Latvia; Montenegro; Netherlands; North Macedonia; Poland; Portugal; Romania; Russia; Serbia; Slovakia; Slovenia; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02021318, source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02021318-2024-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
- Acronym: Dolomites
- Condition: Anemia in Chronic Kidney Disease in Non-dialysis Patients
- Intervention (Drug): Roxadustat
- Intervention (Drug): Darbepoetin alfa
- Lead sponsor: Astellas Pharma Europe B.V.
- Lead sponsor class: INDUSTRY
- Collaborator: Kyntra Bio
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Europe B.V. (`cardio:org-astellas-pharma-europe-b-v`)
- Registry lists this organization as a collaborator: Kyntra Bio (`cardio:org-kyntra-bio`)

## Provenance

Content hash: 51fc56e9c8e36cb60da9c40cb9a6302af9f14ad22f1a24c8afc8b57cd3f6fced
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
